Form 4: Teva Pharmaceutical Executive VP Eric Drape Reports Share Transactions

Executive VP of Global Operations at Teva Pharmaceutical Industries, Eric Drape, reports acquisition and disposal of ordinary shares to cover tax obligations related to vesting restricted share units.

Summary

• Eric Drape, Executive VP Global Operations at Teva Pharmaceutical Industries, filed a Form 4.
• On February 28, 2024, Drape acquired 19,515 ordinary shares through vesting of restricted share units and disposed of 9,815 shares to cover tax withholding obligations.
• The sale price of the shares ranged from $13.01 to $13.19, with a weighted average price of $13.116.
• Following the transactions, Drape beneficially owns 9,701 ordinary shares.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on November 13, 2023.
• The restricted share units were granted on February 28, 2020, and vested in four tranches.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation and share transactions. It doesn't contain any information that would significantly impact the sentiment towards the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be an indicator of management's perspective on the company's valuation and future prospects. However, in this case, the transactions are related to vesting of restricted share units and tax obligations, which is a common occurrence.

Comparison to Industry Standards

• Executive compensation packages often include restricted share units that vest over time.
• The sale of shares to cover tax obligations upon vesting is a standard practice among executives in publicly traded companies.
• Rule 10b5-1 trading plans are commonly used by insiders to avoid accusations of insider trading by pre-scheduling trades.

Key Dates